Vaccitech (VACC) Stock Price, News & Analysis

Company Overview

Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious and autoimmunity diseases, and cancers. The company's therapeutic programs include VTP-300, which is in Phase 2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1b/2 clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.

Key Stats

• Today's Range: $0.88 to $1.13
• 50-Day Range: $1.19 to $5.00
• 52-Week Range: $1.64 to $5.10
• Volume: 78,293 shs
• Average Volume: 244,643 shs
• Market Capitalization: $35.15 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

VACC Stock Analysis - Frequently Asked Questions

How were Vaccitech's earnings last quarter?

Vaccitech plc (NASDAQ:VACC) released its quarterly earnings results on Friday, November, 12th. The company reported ($0.13) EPS for the quarter, topping analysts' consensus estimates of ($0.38) by $0.25. The business had revenue of $0.02 million for the quarter, compared to analyst estimates of $1.65 million. Vaccitech had a negative trailing twelve-month return on equity of 23.41% and a negative net margin of 409.18%.

When did Vaccitech IPO?

Vaccitech (VACC) raised $110 million in an initial public offering on Friday, April 30th 2021. The company issued 6,500,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, Jefferies, Barclays and William Blair acted as the underwriters for the IPO and H.C. Wainwright & Co., LLC was co-manager.

What other stocks do shareholders of Vaccitech own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Vaccitech investors own include Intel (INTC), Johnson & Johnson (JNJ), Snap (SNAP), TJX Companies (TJX), Walt Disney (DIS), NIO (NIO) and Okta (OKTA).

Company Calendar

• Last Earnings: 11/12/2021
• Today: 5/03/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:VACC
• CIK: 1828185
• Web: www.vaccitech.co.uk
• Phone: 44-18-6581-8808
• Fax: N/A
• Employees: 33
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($1.43)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $5.34 million
• Net Margins: -409.18%
• Pretax Margin: -442.00%
• Return on Equity: -23.41%
• Return on Assets: -20.85%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 15.26
• Quick Ratio: 15.26

Sales & Book Value

• Annual Sales: $13.42 million
• Price / Sales: 2.62
• Cash Flow: $0.05 per share
• Price / Cash Flow: 19.30
• Book Value: $6.52 per share
• Price / Book: 0.14

Miscellaneous

• Outstanding Shares: 38,547,000
• Free Float: 36,234,000
• Market Cap: $35.15 million
• Optionable: Not Optionable
• Beta: -0.40